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focus on the use of Angiotensin Converting Enzyme Inhibitors 
(ACE-I).
Methods A Europe-wide web-based survey and a sub-sequent 
DELPHI questionnaire was developed in the con-text of EU’s 
Seventh Framework Programme under grant agreement 
n°6 02 295 using standard recommendations for survey design. 
The questionnaire consisted of 23 ques-tions addressing differ-
ent aspects of drug therapy for HF in children. Use patterns 
of ACE-I i.e. dosage by age group, effectiveness and toxicity 
assessment according to HF ae-tiology where investigated. 
Clinicians from 204 different hospitals of 39 European coun-
tries were invited via e-mail to participate. The subsequent 
DELPHI process discussed controversial responses within a 
selected expert panel in two rounds.
Results The response rate of the survey had been 50%. The 
survey delivered valuable information about thcurrent paedi-
atric heart failure therapy, especially with regard to the pat-
tern of ACE-I use. Enalapril seems to be already the ACE-
inhibitor of choice for children and ad-olescents. A suitable 
formulation and knowledge about dosing as well as adverse 
events might offer Enalapril also for neonates and infants. 
Several controversial aspects which were identified within the 
survey and which are re-lated to paediatric heart failure ther-
apy had been put up for discussion to the DELPHI expert 
panel. They showed a high degree of consensus in their pro-
fessional criteria about most of the contents presented for dis-
cussion. Pos-sible starting points in the way towards a 
standardisation of paediatric heart failure therapy were identi-
fied. With re-gard to non-consensus statements, DELPHI 
experts pro-vided a better visibility to some aspects of clinical 
practice with greater disparity of opinio Diagnostic and thera-
peu-tic approachesns among physicians.
Conclusion This survey and the subsequent DELPHI question-
naire provided an overview of the clinical treat-ment routine 
of paediatric HF across Europe. ACE-I seem to be a crucial 
part of the treatment strategies. Consensus but also still con-
troversial aspects of clinical practice rou-tines for a safe and 
effective use of heart failure treatment for children in Europe 
were identified.
The research leading to these results has received funding
from the EU’s Seventh Framework Programme (FP7/2007-
2013) under grant agreement n°6 02 295 (LENA).
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Background Omnitrope (somatropin) was the first bi-osimilar
approved by the European Medicine Agency in 2006. Since
somatropin is one of the biological products most commonly
prescribed to children and adolescents, a study was performed
with the aim to evaluate the pre-scription of this drug in the
Italian paediatric population. To the best of our knowledge,
no drug utilisation studies evaluated the prescription profile of
biosimilars in the pe-diatric population.
Methods Data collected in healthcare administrative databases
of Lombardy region, Italy, in the 2004–2012 period were
analysed. Children and adolescents who received prescriptions
of somatropin (H01AC01code of the Anatomical Therapeutic
Chemical classification sys-tem) for at least two consecutive
years were identified as prevalent cases. Subjects were defined
incident cases if they had no somatropin prescriptions in the
previous 2 years. Prevalence and incidence of somatropin pre-
scrip-tion were estimated by gender, age group and observa-
tion year. Moreover, each youth with the first prescrip-tion
(index prescription, IP) in the 2006–2010 period was moni-
tored for 24 months, and somatropin prescriptions were ana-
lysed to evaluate if a switch between products occurred. In
switchers, the occurrence of specialist vis-its and/or hospitaliza-
tions in the 60 days preceding the change was checked.
Results During 2012, the prevalence of somatropin pre-scrip-
tion in Lombardy region was 12.0 per 10,000, with an inci-
dence of 2.8 per 10 000. Both prevalence and inci-dence
increased across time (from 9.6 and 1.6 per 10 000 in 2004,
respectively). The prevalence was greater in boys than in girls
(14 versus 10 per 10,000), and increased with increasing age
(from 2.7 in pre-schoolers to 21.1 per 10 000 in adolescents).
A total of 1415 children had the somatro-pin index prescrip-
tion in the 2006–2010 period. Only 98 of them (7%) started
with the biosimilar Omnitrope. The percentage of children
starting with the biosimilar slightly increased with increasing
age, from 4.9% in the 1–5 years old to 7.5% in the adoles-
cents. In all, 17 out of the 98 sub-jects (17.3%) with biosimi-
lar as IP switched to another so-matropin product during the
24 months after the starting date. Of the 1317 children who
started with a ‘branded’ somatropin, 47 (3.6%) switched to
another products (no one to Omnitrope). The rate of switch
was higher in pre-school aged children (3 out of 10) and
decreased with in-creasing age (5 out of 45 in adolescents).
On the contrary, the frequency of switch in subjects with
other somatropin products did not change among age groups.
Only 4 out of 17 subjects had a specialist visit and/or an
hospitalisation in the 60 days before the switch from bio-simi-
lar to ‘branded’ products, while in the non-biosimilar group, a
specialist visit and/or hospital admission was re-corded for 26
out of 47 children.
Conclusion Only 7% of incident (naïve) cases started with the
biosimilar somatropin. Subjects who started with the biosimilar
switched more frequently to anoth-er product and the change
was less likely preceded by a specialist visit.
PP-7 THE SAFE-PEDRUG INITIATIVE: AN OPPORTUNITY FOR
ACADEMIA TO CLOSE THE GAP
1De Bruyne, 2Vande Walle, 3The SAFE-PEDRUG consortium. 1Ghent University, GHENT,
Belgium; 2Ghent University Hospital, GHENT, Belgium; 3Ghent University, Ghent University
Hospital, KULeuven and VUB, GHENT, LEUVEN AND BRUSSELS, Belgium
10.1136/archdischild-2017-esdppp.73
Background The Paediatric Regulation1 was launched ten years
ago. As was also identified in the ten year report2, this regula-
tion has had a positive impact on paediatric research in
Europe. However, some specific patient pop-ulations (such as
neonates, critically ill children, children with comorbidities) do
not receive enough attention in paediatric drug development.
Furthermore, the top-down approach (from adults to children)
results in considerable delays in making medicines available to
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children. For most of the drugs long term follow-up is
missing.
Methods The SAFE-PEDRUG project was initiated in Belgium in
2014 and is a collaboration of experts in pae-diatrics, pharma-
ceutical sciences, veterinary medicine, and ethics of three Belgian
universities: Ghent Universi-ty, KULeuven, and Vrije Universiteit
Brussel. An advisory board and stakeholder group consisting of
national and international stakeholders support this consortium
in the valorisation of results.
Results The SAFE-PEDRUG project explored the value of the
porcine juvenile animal model3 and PK modelling4 (population
pharmacokinetics and physiological-ly based pharmacokinetic
modelling) in providing prior paediatric PK/PD knowledge,
before the actual adult trials have been completed. For the
evaluation of this approach, three case compounds were
selected: des-mopressin, lisinopril, and fluoroquinolones. The
results of the models are plotted against human paediatric
data, including data in neonates and critically ill children.
Discussion A close collaboration of experts and stake-holders
can help to tailor paediatric clinical trials to the needs of chil-
dren. Pharmaceutical industry and regulato-ry authorities are
key players in the paediatric drug de-velopment process. How-
ever, academia can also play an important role in rendering
the paediatric drug development process more efficient by
development and correct use of innovative tools. Besides, aca-
demia should defend the rights of the most important stake-
holders: patients and their parents. During the SAFE-PEDRUG
project additional opportunities for academia have been identi-
fied: initiation of networking; centralisation in registries and
networks to improve transparency and efficiency; and educa-
tion of paediatric clinical pharmacologists.
Acknowledgements The SAFE-PEDRUG project re-ceived a
grant for Strategic Basic Research of the Agen-cy for Innova-
tion by Science and Technology in Flanders (IWT-SBO
130033).
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Background Nowadays, academic researchers, pharma-ceutical
companies and regulatory authorities are more aware of the
need for paediatric drug research. Conse-quently, more aca-
demic and industry-driven paediatric trials are conducted to
evaluate the efficacy and safety of new drugs and to a lesser
extent of off-patent and off-la-bel drugs. However little infor-
mation is available on the burden associated with participating
in clinical trials for the patients and their family/caregivers. In
attempt of be-coming a Centre of Excellence in paediatric
drug research it is important for us to fully understand this
burden.
Methods This is a retrospective, single centre, observa-tional
study. A questionnaire will be designed focusing on the overall
costs and time investment for the participants and their care-
givers. Topics of interest will be absenteeism at school, at
work or in leisure; number of specific study related visits (out
of standard of care); financial reward by the sponsor; etc.
Additional questions will gauge the per-ception and experience
of the patients and their parents. We will contact the parents
of patients who participated in either an academic or industry
driven trial between 2010 and 2017 at the departments of
paediatric nephrol-ogy and gastroenterology of the Elisabeth
Children’s Hospital (Ghent University Hospital). We will dis-
play the results of this questionnaire by using descriptive
statistics.
Discussion By evaluating the results, we will identify what
brings most burden to patients and their family/caregivers in
participating in clinical trials. This will enable us to better
understand this burden and eventually to anticipate by more
and better information and support during the participation.
This may increase compliance, especially important in drug tri-
als. The data can help us to include these aspects in discus-
sions with both ethical committee and sponsors (industry)
during the develop-ment of the study design and during nego-
tiation of the clinical trial agreement (inclusive of some com-
pensation) between research centres and sponsors.
Acknowledgements The survey is an initiative of the SAFE-
PEDRUG project (IWT-SBO 130033), supported by the
Agency for Innovation by Science and Technology in Flanders
(IWT).
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Background Clinical trial discontinuation represents a waste in
research resources and raises ethical concerns. Conduct of
clinical trials is perceived to be more challeng-ing in children
than in adults. The aim of this study was to evaluate the
impact of the age of participants on comple-tion rates of
randomised controlled trials (RCTs).
Methods This is a cross-sectional study on RCTs regis-tered in
the ClinicalTrials.gov database. All RCTs registered in the data-
base from its inception date (February 29, 2000) to December
31, 2016, were extracted. RCTs with unknown recruitment
status or registered more than 60 days after their start date
were excluded. Remaining RCTs were classified according to
their recruitment status: active, completed, and discontinued
trials, and according to the age of participants: children (0–17
years), adults (18 years), and mixed age populations. Further
RCT charac-teristics were assessed using information registered
in the database: study location, funding source, year of reg-
istration, study phase, study design, type of intervention eval-
uated, blinding procedure, study duration, and enroll-ment
achieved. A logistic regression model was applied to assess the
impact of participant’s age category on trial completion while
controlling for other potentially rele-vant trial characteristics.
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